Apoquel

RSS

oclacitinib maleate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 01/08/2018

Authorisation details

Product details
Name
Apoquel
Agency product number
EMEA/V/C/002688
Active substance
oclacitinib maleate
International non-proprietary name (INN) or common name
oclacitinib maleate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QD11AH90
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
12/09/2013
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

26/07/2018 Apoquel - EMEA/V/C/002688 - R/0013

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Agents for dermatitis
  • excluding corticosteroids

Therapeutic indication

Treatment of clinical manifestations of Pruritus associated with Allergic Dermatitis in dogs.

Treatment of clinical manifestations of Atopic Dermatitis in dogs.

Assessment history

How useful was this page?

Add your rating